LifeSci Capital analyst Cory Jubinville initiated coverage of Crinetics with an Outperform rating and $57 price target. The clinical stage biotechnology company has a well-differentiated platform to generate highly specific small molecules targeting G-protein-coupled receptors, or GPCRs, in endocrinology and is "rapidly emerging as a leader in endocrinology," the analyst tells investors. Lead asset paltusotine, a once-daily oral small molecule somatostatin agonist, has three "meaningful" data readouts over the next 12 months as well as a "quickly maturing, well-positioned, and scientifically-sound pipeline," the firm added.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRNX:
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics price target lowered to $41 from $50 at JMP Securities
- Crinetics reports Q4 EPS (84c), consensus (82c)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
